• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
COVID-19 Testing

Universal Masking and COVID-19 Infection Rates in Healthcare Personnel

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • Wang et al. (JAMA, 2020) assessed whether a program of universal masking in a large healthcare system was associated with the SARS-CoV-2 infection rate among healthcare personnel

METHODS:

  • Retrospective cohort study
    • Mass General Brigham (MGB) |12 hospitals 75 000 employees
  • Hospital system initiated a COVID-19 infection reduction strategy that included
    • Systematic SARS-CoV-2 testing of symptomatic healthcare personnel
    •  Universal masking of all healthcare personnel and patients (surgical masks)
  • 3 phases
    • Preintervention period before universal masking: March 1 to 24, 2020
    • Transition period until implementation of universal masking of patients: March 25 to April 5, 2020
      • Lag period to allow for manifestations of symptoms: April 6 to 10, 2020
    • Intervention period; April 11 to 30, 2020
  • Positivity rate
    • Numerator: First positive test result for all healthcare personnel
    • Denominator: Healthcare personnel who never tested positive plus those who tested positive that day
  • Statistical analysis
    • Mean trends calculated based on overall slope of each period was calculated using linear regression
    • Change in overall slope compared between the preintervention vs intervention periods

RESULTS:

  • 9850 Healthcare Personnel underwent testing
    • Positive results: 12.9% | Median age, 39 years
      • 73% female | 7.4% physicians or trainees | 26.5% nurses or PAs | 17.8% technologists or nursing support | 48.3% other
    • Preintervention period: SARS-CoV-2 positivity rate increased exponentially from 0% to 21.32% | Weighted mean increase of 1.16% per day | Case doubling time of 3.6 days (95% CI, 3.0 to 4.5 days)
    • Intervention period: SARS-CoV-2 positivity rate decreased linearly from 14.65% to 11.46% | Weighted mean decline of 0.49% per day
    • Net slope change: 1.65% more decline per day compared with the preintervention period (95% CI, 1.13% to 2.15%; P < .001)

CONCLUSION:

  • Universal masking was associated with a decrease in SARS-CoV-2 infection rates among healthcare personnel
  • The authors acknowledge the possibility of confounding due to other transmission prevention measures such as social distancing
  • The authors state that

Randomized trials of universal masking of HCWs during a pandemic are likely not feasible

Nonetheless, these results support universal masking as part of a multipronged infection reduction strategy in health care settings

Learn More – Primary Sources:

Association Between Universal Masking in a Health Care System and SARS-CoV-2 Positivity Among Health Care Workers

Get COVID-19 Research Summaries Direct to Your Phone

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Testing Posts
Next >

Related ObG Topics:

COVID-19, PPE and Second Stage of Labor: Current US Guidance
Surgical Masks Reduce Viral Shedding
ACOG COVID-19 FAQs for Obstetrical Care
NIH COVID-19 Treatment Guidelines

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site